NI201500173A - Preparado farmacéutico - Google Patents

Preparado farmacéutico

Info

Publication number
NI201500173A
NI201500173A NI201500173A NI201500173A NI201500173A NI 201500173 A NI201500173 A NI 201500173A NI 201500173 A NI201500173 A NI 201500173A NI 201500173 A NI201500173 A NI 201500173A NI 201500173 A NI201500173 A NI 201500173A
Authority
NI
Nicaragua
Prior art keywords
solution
pharmaceutical preparation
alpha emitting
selective binder
emitting radionuclide
Prior art date
Application number
NI201500173A
Other languages
English (en)
Inventor
Olsen Frenvik Janne
B Ryan Olav
Cuthbertson Alan
Original Assignee
Bayer As
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Bayer As filed Critical Bayer As
Publication of NI201500173A publication Critical patent/NI201500173A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
    • A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
    • A61K51/04—Organic compounds
    • A61K51/08—Peptides, e.g. proteins, carriers being peptides, polyamino acids, proteins
    • A61K51/10—Antibodies or immunoglobulins; Fragments thereof, the carrier being an antibody, an immunoglobulin or a fragment thereof, e.g. a camelised human single domain antibody or the Fc fragment of an antibody
    • A61K51/1075—Antibodies or immunoglobulins; Fragments thereof, the carrier being an antibody, an immunoglobulin or a fragment thereof, e.g. a camelised human single domain antibody or the Fc fragment of an antibody the antibody being against an enzyme
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
    • A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
    • A61K51/04—Organic compounds
    • A61K51/08—Peptides, e.g. proteins, carriers being peptides, polyamino acids, proteins
    • A61K51/10—Antibodies or immunoglobulins; Fragments thereof, the carrier being an antibody, an immunoglobulin or a fragment thereof, e.g. a camelised human single domain antibody or the Fc fragment of an antibody
    • A61K51/1045—Antibodies or immunoglobulins; Fragments thereof, the carrier being an antibody, an immunoglobulin or a fragment thereof, e.g. a camelised human single domain antibody or the Fc fragment of an antibody against animal or human tumor cells or tumor cell determinants
    • A61K51/1051—Antibodies or immunoglobulins; Fragments thereof, the carrier being an antibody, an immunoglobulin or a fragment thereof, e.g. a camelised human single domain antibody or the Fc fragment of an antibody against animal or human tumor cells or tumor cell determinants the tumor cell being from breast, e.g. the antibody being herceptin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
    • A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
    • A61K51/04—Organic compounds
    • A61K51/08—Peptides, e.g. proteins, carriers being peptides, polyamino acids, proteins
    • A61K51/10—Antibodies or immunoglobulins; Fragments thereof, the carrier being an antibody, an immunoglobulin or a fragment thereof, e.g. a camelised human single domain antibody or the Fc fragment of an antibody
    • A61K51/1093—Antibodies or immunoglobulins; Fragments thereof, the carrier being an antibody, an immunoglobulin or a fragment thereof, e.g. a camelised human single domain antibody or the Fc fragment of an antibody conjugates with carriers being antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Physics & Mathematics (AREA)
  • Optics & Photonics (AREA)
  • Immunology (AREA)
  • Oncology (AREA)
  • Cell Biology (AREA)
  • Dermatology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Dispersion Chemistry (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Engineering & Computer Science (AREA)
  • Nanotechnology (AREA)
  • Saccharide Compounds (AREA)
  • Extraction Or Liquid Replacement (AREA)

Abstract

Un método para generar una solución purificada de por lo menos un complejo de radionúclido emisor alfa. El método comprende poner en contacto una solución del complejo de radionúclido emisor alfa y por lo menos un núclido hijo que tiene por lo menos un ligante selectivo para los núclidos hijos subsiguientemente separar la solución del ligante selectivo. También, un método para separar por lo menos un radionúclido hijo de una solución que comprende por lo menos un complejo de radionúclido emisor alfa. El método comprende poner en contacto la solución que tiene por lo menos un ligante selectivo para los núclidos hijos.
NI201500173A 2013-06-05 2015-12-04 Preparado farmacéutico NI201500173A (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
GBGB1310028.4A GB201310028D0 (en) 2013-06-05 2013-06-05 Pharmaceutical preparation

Publications (1)

Publication Number Publication Date
NI201500173A true NI201500173A (es) 2016-01-06

Family

ID=48805787

Family Applications (1)

Application Number Title Priority Date Filing Date
NI201500173A NI201500173A (es) 2013-06-05 2015-12-04 Preparado farmacéutico

Country Status (36)

Country Link
US (2) US20160114063A1 (es)
EP (1) EP3003401B1 (es)
JP (1) JP6580559B2 (es)
KR (1) KR102321763B1 (es)
CN (1) CN105592863B (es)
AP (1) AP2015008894A0 (es)
AU (1) AU2014276885B2 (es)
BR (1) BR112015030298A2 (es)
CA (1) CA2914278C (es)
CL (1) CL2015003554A1 (es)
CR (1) CR20150642A (es)
CU (1) CU24535B1 (es)
DK (1) DK3003401T3 (es)
DO (1) DOP2015000294A (es)
EA (1) EA201501174A1 (es)
ES (1) ES2782624T3 (es)
GB (1) GB201310028D0 (es)
HR (1) HRP20200456T1 (es)
IL (1) IL242704B (es)
LT (1) LT3003401T (es)
MA (1) MA38650B1 (es)
MX (1) MX366028B (es)
MY (1) MY180717A (es)
NI (1) NI201500173A (es)
PE (1) PE20160215A1 (es)
PH (1) PH12015502715A1 (es)
PL (1) PL3003401T3 (es)
PT (1) PT3003401T (es)
RS (1) RS60091B1 (es)
SA (1) SA515370233B1 (es)
SG (1) SG11201509856RA (es)
SI (1) SI3003401T1 (es)
TN (1) TN2015000527A1 (es)
UA (1) UA120352C2 (es)
WO (1) WO2014195423A1 (es)
ZA (1) ZA201600027B (es)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB201600161D0 (en) * 2016-01-05 2016-02-17 Bayer As Isotope purification method
GB201600158D0 (en) * 2016-01-05 2016-02-17 Bayer As Purification method
AU2022210371A1 (en) 2021-01-22 2023-07-20 Bayer Aktiengesellschaft Lrrc15 antibodies and conjugates thereof
NO347755B1 (en) * 2021-10-21 2024-03-18 Blue Wave Therapeutics Gmbh Peptide-coupled alginate gels comprising radionuclides

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5749042A (en) * 1997-01-28 1998-05-05 Battelle Memorial Institute Bismuth generator method
GB0308731D0 (en) * 2003-04-15 2003-05-21 Anticancer Therapeutic Inv Sa Method of radiotherapy
WO2010126979A1 (en) * 2009-04-29 2010-11-04 Bio-Rad Laboratories, Inc. Purification of immunoconjugates
GB201002508D0 (en) 2010-02-12 2010-03-31 Algeta As Product
GB201105298D0 (en) * 2011-03-29 2011-05-11 Algeta Asa Pharmaceutical preparation

Also Published As

Publication number Publication date
TN2015000527A1 (en) 2017-04-06
ZA201600027B (en) 2018-07-25
UA120352C2 (uk) 2019-11-25
EP3003401B1 (en) 2020-01-15
NZ714737A (en) 2021-02-26
SI3003401T1 (sl) 2020-06-30
GB201310028D0 (en) 2013-07-17
MA38650B1 (fr) 2019-05-31
AU2014276885A1 (en) 2015-12-17
PH12015502715B1 (en) 2016-03-28
CN105592863A (zh) 2016-05-18
MA38650A1 (fr) 2018-03-30
PT3003401T (pt) 2020-04-09
SG11201509856RA (en) 2015-12-30
KR102321763B1 (ko) 2021-11-05
KR20160030893A (ko) 2016-03-21
DK3003401T3 (da) 2020-04-06
CN105592863B (zh) 2020-03-10
CA2914278A1 (en) 2014-12-11
PE20160215A1 (es) 2016-05-22
HRP20200456T1 (hr) 2020-06-26
EP3003401A1 (en) 2016-04-13
CL2015003554A1 (es) 2016-07-15
PH12015502715A1 (en) 2016-03-28
BR112015030298A2 (pt) 2017-07-25
CU24535B1 (es) 2021-07-02
DOP2015000294A (es) 2016-03-15
CR20150642A (es) 2016-07-22
JP2016521700A (ja) 2016-07-25
SA515370233B1 (ar) 2019-05-30
WO2014195423A1 (en) 2014-12-11
JP6580559B2 (ja) 2019-09-25
AU2014276885B2 (en) 2018-12-06
MX2015016726A (es) 2016-06-28
US20220023449A1 (en) 2022-01-27
MY180717A (en) 2020-12-07
LT3003401T (lt) 2020-06-25
EA201501174A1 (ru) 2016-10-31
ES2782624T3 (es) 2020-09-15
RS60091B1 (sr) 2020-05-29
PL3003401T3 (pl) 2020-07-27
CU20150174A7 (es) 2016-06-29
IL242704B (en) 2020-06-30
AP2015008894A0 (en) 2015-12-31
US20160114063A1 (en) 2016-04-28
CA2914278C (en) 2022-11-01
MX366028B (es) 2019-06-21

Similar Documents

Publication Publication Date Title
CY1121750T1 (el) Cot διαμορφωτες και μεθοδοι χρησης αυτων
ECSP18053055A (es) Agonista triple de receptores de glucagón/glp-1/gip
CL2018000088A1 (es) Métodos para fabricar un compuesto elastómero reforzado con sílice y productos que lo contienen
ECSP17010156A (es) Compuestos aminopirimidinilo como inhibidores jak
CR20160257A (es) Anticuerpos e inmunoconjugados anti-cd33
DOP2015000261A (es) Compuesto peptídico como activador de los receptores del glp-1 y del gip
CL2018000302A1 (es) Proteínas de fusión de factor ix y métodos para producirlas y utilizarlas
CR20150049A (es) Anticuerpos e inmunoconjugados anti-cd79b
IL237525A0 (en) A method for labeling a prostate-specific membrane antigen ligand with a radioactive isotope
AR115788A2 (es) Dispositivos de decodificación y codificación, y método de codificación, en un sistema de audio de canales múltiples
CL2018000087A1 (es) Métodos para fabricar un compuesto elastómero reforzado con sílice y productos que lo contienen
EA201792612A1 (ru) 6-аминохинолин-3-карбонитрилы в качестве модуляторов cot
NI201500173A (es) Preparado farmacéutico
BR112015032268A2 (pt) suporte para um medicamento de dose unitária, máquina para fabricar um suporte de medicamento e método para a fabricação de um suporte de medicamento
CO2017010808A2 (es) Sistemas y métodos para la vigilancia activa del cancer de próstata
CL2015002837A1 (es) Compuestos de piridinilpirazoloquinolina.
CL2015002358A1 (es) Compuestos bicíclicos.
EA201890828A1 (ru) Оптимизированная таблетка с высокой дозой активного соединения, содержащая месалазин
CU20160069A7 (es) Sistema multiparticulado para administrar drogas
BR112017002139A2 (pt) ?método para preparar um composto?
CL2015003268A1 (es) Aparato y métodos para estabilizar roca
UY35823A (es) Profármacos de antagonista de nmda
CL2017001900A1 (es) Remoción de radionúclidos de mezclas
FR3025354B1 (fr) Creation d'isotopes par reactions nucleaires en chaine
CO7141421A2 (es) Formulación farmacéutica que tiene estabilidad mejorada